BTAI - BioXcel Therapeutics, Inc.

QQQ $ 441.33 $ 0.96 (0.22 %)

DIA $ 394.43 $ 3.52 (0.9 %)

SPY $ 520.56 $ 2.98 (0.58 %)

TLT $ 90.69 $ 0.44 (0.49 %)

GLD $ 219.78 $ 0.00 (0 %)

Previous Close

$ 2.305

Open

$ 2.26

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.23 - $ 2.42

52 Week Range

$ 1.91 - $ 29.56

Volume

665,423

Average Volume

Market Cap

71.15M

Beta (5Y Monthly)

$ 1.51

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	03-22-2024	12-31-2023	10-K
3	11-14-2023	09-30-2023	10-Q
4	08-14-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-16-2023	12-31-2022	10-K
7	11-14-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	03-11-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-10-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-12-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	08-14-2020	06-30-2020	10-Q
17	05-12-2020	03-31-2020	10-Q
18	03-09-2020	12-31-2019	10-K
19	11-14-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	03-12-2019	12-31-2018	10-K
23	11-09-2018	09-30-2018	10-Q
24	08-08-2018	06-30-2018	10-Q
25	05-14-2018	03-31-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on BioX...
05/10/2024 11:57:59

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

BioXcel Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:11:11

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of ...

BioXcel Therapeutics Announces Late-Breaki...
04/24/2024 14:33:01

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's...

HC Wainwright & Co. Reiterates Buy on BioX...
04/23/2024 10:28:58

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

BioXcel Therapeutics Reveals Plan For Eval...
04/22/2024 11:08:00

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No...

BioXcel Therapeutics Announced Details Reg...
04/10/2024 11:06:07

BioXcel Therapeutics shares are trading lo...
03/25/2024 11:23:13

BioXcel Therapeutics Announces $25M Regist...
03/25/2024 11:03:29

BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence...

HC Wainwright & Co. Reiterates Buy on BioX...
03/18/2024 10:54:31

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

BioXcel Therapeutics Reported That The Eur...
03/15/2024 11:02:05

The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and...

Canaccord Genuity Maintains Buy on BioXcel...
03/14/2024 11:26:33

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price targe...

B of A Securities Maintains Buy on BioXcel...
03/13/2024 14:32:56

B of A Securities analyst Geoff Meacham maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target ...

BioXcel Therapeutics shares are trading hi...
03/12/2024 13:08:04

BioXcel Therapeutics' Cash And Cash Equiva...
03/12/2024 11:04:41

BioXcel Therapeutics Q4 GAAP EPS $(0.76) B...
03/12/2024 11:03:31

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of ...

Earnings Scheduled For March 12, 2024
03/12/2024 09:35:47

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

BioXcel Therapeutics's Earnings Outlook
03/11/2024 15:02:41

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
02/27/2024 21:31:08

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
02/14/2024 17:31:14

why-bioxcel-therapeutics-shares-are-rising-tuesday

Why BioXcel Therapeutics Shares Are Rising...
02/13/2024 17:56:08

BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA...